BR112022015601A2 - Grandes vetores genéticos e dispensação e usos dos mesmos - Google Patents

Grandes vetores genéticos e dispensação e usos dos mesmos

Info

Publication number
BR112022015601A2
BR112022015601A2 BR112022015601A BR112022015601A BR112022015601A2 BR 112022015601 A2 BR112022015601 A2 BR 112022015601A2 BR 112022015601 A BR112022015601 A BR 112022015601A BR 112022015601 A BR112022015601 A BR 112022015601A BR 112022015601 A2 BR112022015601 A2 BR 112022015601A2
Authority
BR
Brazil
Prior art keywords
dispension
genetic vectors
large genetic
strc
splicing
Prior art date
Application number
BR112022015601A
Other languages
English (en)
Portuguese (pt)
Inventor
R Holt Jeffrey
Shubina-Oleinik Olga
Original Assignee
Childrens Medical Ct Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Ct Corp filed Critical Childrens Medical Ct Corp
Publication of BR112022015601A2 publication Critical patent/BR112022015601A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
    • C07K2319/92—Fusion polypeptide containing a motif for post-translational modification containing an intein ("protein splicing")domain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/40—Systems of functionally co-operating vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR112022015601A 2020-02-07 2021-02-05 Grandes vetores genéticos e dispensação e usos dos mesmos BR112022015601A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062971555P 2020-02-07 2020-02-07
PCT/US2021/016720 WO2021158854A2 (en) 2020-02-07 2021-02-05 Large gene vectors and delivery and uses thereof

Publications (1)

Publication Number Publication Date
BR112022015601A2 true BR112022015601A2 (pt) 2022-10-11

Family

ID=77200426

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022015601A BR112022015601A2 (pt) 2020-02-07 2021-02-05 Grandes vetores genéticos e dispensação e usos dos mesmos

Country Status (8)

Country Link
US (1) US20230090778A1 (cg-RX-API-DMAC7.html)
EP (1) EP4100518A4 (cg-RX-API-DMAC7.html)
JP (1) JP7846626B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220139924A (cg-RX-API-DMAC7.html)
AU (1) AU2021216410A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022015601A2 (cg-RX-API-DMAC7.html)
CA (1) CA3170709A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021158854A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL325122A (en) 2018-02-22 2026-02-01 Akouos Inc Compositions and methods for treating non-age-related hearing impairment in humans
JP2021530227A (ja) 2018-07-13 2021-11-11 アコーオス インコーポレイテッド 非症候性感音性聴力喪失の治療方法
US12667628B2 (en) 2019-07-03 2026-06-30 Children's Medical Center Corporation Compositions and methods for gene replacement
CA3168055A1 (en) 2020-02-21 2021-08-26 Emmanuel John Simons Compositions and methods for treating non-age-associated hearing impairment in a human subject
US20240352086A1 (en) * 2021-08-24 2024-10-24 The Regents Of The University Of California Compositions and methods comprising lipid associated transmembrane domains
CN116836975A (zh) * 2022-03-25 2023-10-03 上海玮美基因科技有限责任公司 一种耳蜗和/或前庭细胞特异性启动子及其应用
CN117106824B (zh) * 2022-05-17 2025-09-02 上海佑音医药生物科技有限公司 一种治疗听力损伤的双载体系统及其应用
EP4724470A1 (en) 2023-06-12 2026-04-15 Children's Hospital Medical Center Aav-cftr vectors and methods of using same
CN116925239B (zh) * 2023-07-17 2024-10-18 苏州星奥拓维生物技术有限公司 双载体系统表达Otof基因的组合物和方法
CN118308390A (zh) * 2024-04-24 2024-07-09 广州派真生物技术有限公司 一种内含肽联用载体及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002046208A2 (en) * 2000-11-01 2002-06-13 Elusys Therapeutics, Inc. Method of producing biospecific molecules by protein trans-splicing
CN101595228A (zh) * 2005-07-21 2009-12-02 艾博特公司 包括sorf构建体的多基因表达和使用多蛋白、前体蛋白和蛋白酶解的方法
JP2013509188A (ja) * 2009-10-30 2013-03-14 アボット・ラボラトリーズ Sorf構築物および複数の遺伝子発現
JP6177780B2 (ja) * 2011-09-28 2017-08-09 エラ、ビオテック、ソシエダッド、アノニマEra Biotech, S.A. スプリットインテインおよびその使用
CA2979120A1 (en) 2015-03-03 2016-09-09 Fondazione Telethon Multiple aav vector system for expressing genes over 5 kilobases, comprising at least one degradation signal and uses thereof
WO2017209280A1 (ja) * 2016-06-03 2017-12-07 国立大学法人鹿児島大学 酵母と断片化cDNAライブラリーを用いたタンパク質の新しい同定法
KR20240007715A (ko) * 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
MA47820A (fr) * 2017-03-10 2020-01-15 Genethon Traitement de la glycogénose de type iii
WO2018226602A1 (en) * 2017-06-05 2018-12-13 Research Institute At Nationwide Children's Hospital Enhanced modified viral capsid proteins
JP2021530227A (ja) * 2018-07-13 2021-11-11 アコーオス インコーポレイテッド 非症候性感音性聴力喪失の治療方法
CA3116606A1 (en) 2018-10-15 2020-04-23 Fondazione Telethon Intein proteins and uses thereof

Also Published As

Publication number Publication date
KR20220139924A (ko) 2022-10-17
JP7846626B2 (ja) 2026-04-15
CA3170709A1 (en) 2021-08-12
EP4100518A4 (en) 2024-06-05
JP2023512824A (ja) 2023-03-29
AU2021216410A1 (en) 2022-09-01
US20230090778A1 (en) 2023-03-23
WO2021158854A2 (en) 2021-08-12
WO2021158854A3 (en) 2021-09-10
EP4100518A2 (en) 2022-12-14

Similar Documents

Publication Publication Date Title
WO2021158854A3 (en) Large gene vectors and delivery and uses thereof
CY1125212T1 (el) Συνθεσεις τροποποιημενου mrna
D'Andrea et al. The mitochondrial translation machinery as a therapeutic target in Myc-driven lymphomas
BR112017018728A2 (pt) sistema de vetor para expressar a sequência de codificação de um gene de interesse em uma célula, célula hospedeira, composição farmacêutica, método para tratar e/ou prevenir uma patologia ou doença, uso de uma sequência de nucleotídeo de um sinal de degradação em um sistema de vetor e método para diminuir a expressão de uma proteína na forma truncada
BR112022000641A2 (pt) Modificação genética de célula efetora imune e uso da mesma
DOP2020000071A (es) Proteínas trispecificas y métodos de uso
MX2021006646A (es) Vector viral adenoasociado recombinante para el suministro de genes.
BR112022009895A2 (pt) Construtos de terapia de gene de microdistrofina e usos dos mesmos
PH12018502361A1 (en) Gdf15 fusion proteins and uses thereof
WO2020198509A3 (en) Modified oligonucleotides with increased stability
BR112018008326A2 (pt) composições e métodos para o tratamento de câncer
PE20200006A1 (es) Nuevas moleculas de union antigeno biespecificas capaces de unirse especificamente cd40 y a fap
BR112017015567A2 (pt) proteína gl de citomegalovírus recombinante ou fragmento de formação de complexo da mesma, complexo de citomegalovírus, ácido nucleico isolado, célula hospedeira, e, composição imunogênica
BR112019011860A2 (pt) proteína de fusão insulina-fc, sequência de ácido nucleico recombinante que codifica a mesma, vetor, célula eucariótica modificada, kit e método para tratar ou prevenir o diabetes autoimune
BR112019000693A2 (pt) composições de muc1- car e métodos para uso
CL2024001186A1 (es) Compuestos fosfolípidos y usos de estos
BR112018068189A2 (pt) proteínas de ligação induzíveis e métodos de uso
AU2016256582A8 (en) Oncolytic adenovirus encoding a B7 protein
BR112022018254A2 (pt) Anticorpos isolados, ácido nucleico isolado, vetor ou conjunto de vetores, célula hospedeira, métodos para produzir um anticorpo, para tratar um distúrbio e para tratar ag em um paciente, composição e uso de um anticorpo
BR112018016443A2 (pt) sistema de transposon replicativo
WO2021126961A8 (en) Enhanced production of histidine, purine pathway metabolites, and plasmid dna
MX2022005670A (es) Composiciones y metodos para recombinacion de alta eficiencia de moleculas de arn.
BR112022008861A2 (pt) Construto de ácido nucleico, vetor, nanopartícula lipídica, célula, composição para uso na expressão de retinosquisina, método para integrar uma sequência de codificação, e, método para modificar um gene rs1
CU24542B1 (es) Proteínas inhibidoras de insectos provenientes de paenibacillus popilliae
CL2024002556A1 (es) Proteína de la cápsida de aavrh74; partícula de aavrh74; composición; y su uso.